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ABSTRACT Toxoplasma gondii is an intracellular parasite that has infected one-third
of humans. The infection is permanent because the replicative form (tachyzoite) con-
verts into a latent tissue cyst form (bradyzoite) that evades host immunity and is im-
pervious to current drugs. The continued presence of these parasitic cysts hinders
treatment and leads to chronic infection that has been linked to behavioral changes
in rodents and neurological disease in humans. How these behavioral changes oc-
cur, and whether they are due to parasite manipulation or the host response to in-
fection, remains an outstanding question. We previously showed that guanabenz
possesses antiparasitic activity; here, we show that guanabenz reproducibly lowers
brain cyst burden up to 80% in chronically infected male and female BALB/cJ mice
when given intraperitoneally but not when administered by gavage or in food. Re-
gardless of the administration route, guanabenz reverses Toxoplasma-induced hyper-
activity in latently infected mice. In contrast, guanabenz increases cyst burden when
given to chronically infected C57BL/6J mice yet still reverses Toxoplasma-induced hy-
peractivity. Examination of the brains from chronically infected BALB/cJ and
C57BL/6J mice shows that guanabenz decreases inﬂammation and perivascular cuff-
ing in each strain. Our study establishes a robust model for cyst reduction in
BALB/cJ mice and shows for the ﬁrst time that it is possible to reverse a key behav-
ioral change associated with latent toxoplasmosis. The rescue from parasite-induced
hyperactivity correlates with a decrease in neuroinﬂammation rather than reduced
cyst counts, suggesting that some behavioral changes arise from host responses to
infection.
IMPORTANCE Toxoplasma gondii is a common parasite of animals, including up
to one-third of humans. The single-celled parasite persists within hosts for the
duration of their life as tissue cysts, giving rise to chronic infection. Latent toxo-
plasmosis is correlated with neurological dysfunction in humans and results in
dramatic behavioral changes in rodents. When infected, mice and rats adapt be-
haviors that make them more likely to be devoured by cats, the only host that
supports the sexual stage of the parasite. In this study, we establish a new
mouse model of tissue cyst depletion using a drug called guanabenz and show
that it is possible to reverse a key behavior change back to normal in infected
animals. We also show that the mechanism appears to have nothing to do with
parasite cyst burden but rather the degree of neuroinﬂammation produced by
chronic infection.
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Toxoplasma gondii is a protozoan parasite in the phylum Apicomplexa that perma-nently infects warm-blooded vertebrates and is estimated to have inﬁltrated over 3
billion human hosts (1). Despite the remarkable range of host organisms, felines are the
only species capable of supporting the sexual stage of the parasite’s life cycle. Upon
infecting a host organism, the replicative stage of the parasite (tachyzoite) quickly
converts into a quiescent stage (bradyzoite) that remains encysted in host tissues.
Acute illness usually presents with minor symptoms that resolve within days as chronic
infection is established. Tissue cysts housing bradyzoites are found throughout the host
but primarily accumulate in large numbers in neurons of the central nervous system
(CNS) (2). Bradyzoites can revert to tachyzoites during immune suppression, causing
life-threatening episodes of reactivated toxoplasmosis.
Chronic infection in rodents leads to an array of CNS dysfunction, including altera-
tions in neurotransmitter levels, protein expression, immune responses, and behavior
(3–5). Behavioral changes include hyperactivity, cognitive deﬁcits, and altered anxiety
and fear responses (6–8). These behavioral changes conspire to form the basis of a
popular hypothesis proposing that Toxoplasmamanipulates its rodent hosts to become
easy prey for cats (9). By driving rodent hosts into the gut of feline predators,
Toxoplasma secures progression to the sexual stage of its life cycle and widespread
transmission as oocysts in cat feces. In humans, chronic toxoplasmosis has been
correlated with schizophrenia, bipolar disorder, epilepsy, rage disorder, and sudden-
onset psychosis (10).
How Toxoplasma induces changes in host behavior remains unknown. Previous
efforts to mitigate the behavioral changes caused by Toxoplasma have been unsuc-
cessful. Ceftriaxone treatment can restore the altered glutamate levels and neuronal
morphology in chronically infected mice but failed to reverse infection-induced
changes in behavior (11). Attempts to normalize acetylcholinesterase activity in the CNS
of infected mice using diphenyl diselenide did not restore altered behaviors (12).
Deletion of parasite proteins such as the Toxoplasma AaaH2 tyrosine hydroxylase,
which was hypothesized to manipulate host dopamine levels, did not impact the
parasite’s inﬂuence on host behavior (13). Additionally, mice infected with an attenu-
ated strain incapable of cyst formation continued to display behavioral alterations even
though parasites could no longer be detected in these animals (14).
A means to reliably decrease or eliminate cysts from a chronically infected animal
would be invaluable in dissecting mechanisms underlying Toxoplasma-induced behav-
ioral changes. We previously found that the phosphorylation of Toxoplasma eukaryotic
initiation factor 2 (TgIF2) accompanies the stress-induced conversation of
tachyzoites into bradyzoites (15, 16). As in other eukaryotic cells, phosphorylated eIF2
initiates the integrated stress response (ISR), which leads to preferential translation of
mRNAs that coordinate adaptive changes to stressful stimuli (17). Guanabenz (GA), an
alpha-adrenergic receptor agonist approved to treat hypertension, was recently shown
to also inhibit dephosphorylation of eIF2 (18). After showing that guanabenz inhibits
dephosphorylation of TgIF2, we demonstrated that it curtails growth of tachyzoites in
vitro and prevents reactivation of in vitro-generated bradyzoites (19). In the presence of
guanabenz, in vitro-generated bradyzoites exhibited gross changes in morphology,
suggesting the drug may be cysticidal (19, 20). We subsequently showed that guana-
benz is active against both acute and chronic toxoplasmosis in female BALB/c mice,
reducing brain cyst counts by 75% in those treated for latent toxoplasmosis (20).
Here, we examine the effects of guanabenz on cyst burden using different dosing
and delivery strategies and an additional mouse strain, C57BL/6. We established a new
mouse model in which brain cyst burden is reliably reduced by 70 to 80% with
guanabenz treatment and use this model to test the hypothesis that a reduction in
parasitic cysts would reverse a key behavioral change associated with chronic toxo-
plasmosis. Surprisingly, we found that hyperactivity in chronically infected mice can be
reversed by guanabenz, but the restoration of normal locomotor activity correlates with
decreased neuroinﬂammation rather than brain cyst burden. Importantly, this ﬁnding
supports the idea that, at least for some behaviors, what appears to be host manipu-
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lation is due to the host immune response rather than a presumed neuromodulatory
effector produced by the parasite.
RESULTS
Intraperitoneal guanabenz reduces brain cyst burden in male and female
BALB/cJ mice. We previously reported that guanabenz treatment reduces brain cyst
burden in female BALB/c mice by 69 to 78% (20). We sought to examine whether this
effect is gender speciﬁc by infecting both male and female BALB/cJ mice intraperito-
neally (i.p.) with type II (Pru) parasites. Infection was allowed to progress to the chronic
stage for 3 weeks before treatment with either guanabenz (5 mg/kg of body weight/
day) or vehicle i.p. for 3 weeks (Fig. 1A). Brain cyst burden was quantiﬁed in the
drug-treated mice and compared to the vehicle control. Our ﬁndings establish that
guanabenz treatment yields an 75% reduction of latent brain cysts in both male and
female BALB/cJ mice (Fig. 1B and C). A 73% reduction of brain cysts is observed when
data from both sexes are combined (Fig. 1D). We conclude that guanabenz reproduc-
ibly lowers brain cyst burden in BALB/c mice. As the effect is not gender speciﬁc, we
used only female mice in subsequent experiments.
Our lab has previously established that increasing the dosage of guanabenz to
10 mg/kg does not further reduce cyst burden (20). We next examined whether
extending guanabenz treatment from 3 weeks to 4 or 6 weeks could reduce cyst counts
further (Fig. 1E). Cyst counts remained reduced for the extended drug treatment times,
but no further reduction was observed (Fig. 1F). It should be noted that we did not
perform measurements of tachyzoites in the brain. Despite the mice being asymptom-
atic, low levels of tachyzoites may have been present in the mice that gave rise to the
residual brain cysts that the drug treatment failed to clear. We conclude that guana-
benz treatment results in an impressive and reliable decrease in cyst numbers but it
does not fully eradicate the infection.
Intraperitoneal guanabenz restores normal locomotor activity levels in chron-
ically infected BALB/cJ mice. Hyperactivity is a well-established behavioral change
that occurs in mice with latent toxoplasmosis (13, 21). We reasoned that since guana-
benz could reduce cyst counts upward of 80%, then parasite-induced behaviors may
also be attenuated. To minimize potential effects of guanabenz itself on behavior,
assessment of locomotor activity was performed in the 4-h window before daily drug
dosing, when there is no detectable drug in circulation or brain (22). Locomotor activity
was recorded as total distance traveled (cm) in an open ﬁeld over 30 min. As shown in
Fig. 2A, chronically infected or mock-infected BALB/cJ mice were treated with guana-
benz or vehicle daily for 4 weeks. We observed no change in locomotor activity in
mock-infected mice given guanabenz, and the Toxoplasma-infected mice displayed the
expected hyperactivity (Fig. 2B). Strikingly, the group of chronically infected mice
treated with guanabenz exhibited signiﬁcantly reduced hyperactivity compared to
vehicle-treated mice, nearly reverting to the baseline recorded for uninfected mice
(Fig. 2B).
Oral guanabenz reduces hyperactivity without lowering cyst burden in
BALB/cJ mice. We next examined how administration of guanabenz through oral
routes compared to efﬁcacy of i.p. drug injection. Female BALB/cJ mice were infected
and allowed to progress to chronic infection as before and then were randomized into
groups. Guanabenz or vehicle was administered by i.p. injection, by oral gavage, or in
feed for 3 weeks before locomotor activity was recorded (Fig. 3A). Guanabenz again
reversed parasite-induced hyperactivity to near-baseline levels, regardless of the dosing
route used (Fig. 3B). We also quantiﬁed the brain cyst burden in these mice, again
seeing a dramatic reduction in those treated with i.p. guanabenz. Surprisingly, cyst
counts were not signiﬁcantly altered in the latently infected mice that received gua-
nabenz by intragastric or oral routes, suggesting that rescue from parasite-induced
hyperactivity occurs independently of cyst burden (Fig. 3C).
Guanabenz reduces chronic inﬂammation in infected BALB/cJ mice. As our
previous experiment showed that reduced brain cyst burden is not linked to the
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reversal of hyperactivity, we examined other aspects of neurophysiology that may
explain the effect of guanabenz. It is well established that guanabenz exhibits anti-
inﬂammatory properties in vitro and in vivo (22–24). In vitro, guanabenz has been
shown to decrease the expression of proinﬂammatory cytokines, including IFN-, IL-6,
and TNF- (23, 24). Using RT-qPCR, we determined the mRNA expression levels of these
inﬂammatory cytokines in J774.1 cells, a BALB/c-derived macrophage line (Fig. 4A to E).
Stimulation of these cells using LPS resulted in increased expression of IFN-, TNF-,
IL-6, IL-1, and COX-2; however, guanabenz blocked this effect. These results are
consistent with the abovementioned studies showing that guanabenz has immuno-
modulatory properties.
FIG 1 Effect of guanabenz on brain cyst burden in male and female BALB/cJ mice. (A) Female and male BALB/cJ mice were infected intraperitoneally with 104
Pru tachyzoites. After 21 days, mice were randomized into either vehicle or guanabenz (GA) treatment (5 mg/kg/day i.p.). Mice were dosed for an additional
3 weeks before brains were extracted and cysts were quantiﬁed. (B and C) Males (B) and females (C) showed comparable decreases in cyst burden. Results are
representative of two independent experiments. Error bars indicate standard deviation of the mean. P value determined using an unpaired two-tailed Student
t test: ***, P 0.001; ****, P 0.0001. (D) Results shown are data from both sexes combined. Error bars indicate standard deviation of the mean. P value
determined using an unpaired two-tailed Student t test: ****, P 0.0001. (E) Female BALB/cJ mice were infected intraperitoneally with 104 Pru tachyzoites and
then randomized into either vehicle or GA (5 mg/kg/day i.p.) treatment groups. Drug treatment was initiated after establishment of chronic infection at 21 days.
After 4 weeks of treatment, half of each group was examined for the 4-week time point. The remaining mice were treated for another 2 weeks for a total of
6 weeks before being examined. (F) Brain cyst counts following treatment with GA for 4 and 6 weeks. Results are representative of two independent
experiments. Error bars indicate standard deviation of the mean. P value determined using an unpaired, two-tailed Student t test: ***, P 0.001; ****, P 0.0001.
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We also performed histological examinations of brain sections from BALB/cJ mice
from our intraperitoneal, intragastric, and oral guanabenz studies above using hema-
toxylin and eosin (H&E) staining. In mock-infected control mice, we found that guana-
benz had no effect on baseline inﬂammation (Fig. 4F). Consistent with ﬁndings reported
by others (5), we observed increased neuroinﬂammation in mice with chronic toxo-
plasmosis (Fig. 4G). However, chronically infected mice treated with guanabenz con-
sistently showed reduced neuroinﬂammation, especially the perivascular cufﬁng char-
acteristic of chronic infection, regardless of the drug delivery method used (Fig. 4G).
FIG 2 Guanabenz eliminates Toxoplasma-induced hyperactivity in BALB/cJ mice. (A) One group of BALB/cJ mice was infected with
104 Pru tachyzoites i.p. (Toxo, gray syringe), and the other was mock infected with PBS (Mock, white syringe). Following establishment
of chronic infection at 21 days, both groups were randomized into vehicle or drug (GA 5 mg/kg/day i.p.) treatment groups. (B) After
4 weeks of treatment, locomotor activity was recorded in an unfamiliar 40-cm by 4-cm by 30-cm Plexiglas box, and the total distances
traveled over 30 min were compared. Error bars indicate standard error of the mean. One-way ANOVA, P 0.0019, followed by an
unpaired, two-tailed Student t test: **, P 0.001; #, P 0.1; ns, P 0.1.
FIG 3 Reduction in Toxoplasma-induced hyperactivity is independent of cyst burden. (A) Female BALB/cJ mice were infected i.p. with 104 Pru tachyzoites.
Following establishment of chronic infection at 21 days, mice were randomized into groups and given either guanabenz (GA) or vehicle by different routes (i.p.,
feed, or gavage) for 3 weeks. (B) After 3 weeks of GA treatment, locomotor activity was recorded. Error bars indicate standard error of the mean. Single replicate
with one-way ANOVA, P 0.0022, followed by unpaired, two-tailed Student’s t test: *, P 0.05. (C) After 3 weeks of GA treatment, samples were prepared in
a blind manner and brain cysts were enumerated. Error bars indicate standard deviation of the mean. Single replicate with one-way ANOVA, P 0.0012,
followed by an unpaired, two-tailed Student t test: ns, P 0.5; **, P 0.01; ***, P 0.001; ****, P 0.0001.
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To quantify the reduction in neuroinﬂammation, we used immunohistochemistry
(IHC) to label sections of brain using anti-CD45 antibody, which serves as a general
marker for immune cells by identifying leukocytes (Fig. 5A). Regardless of the admin-
istration route, guanabenz caused a reduction in CD45 cells in chronically infected
BALB/cJ mice (Fig. 5B). No difference in CD45 cells was detected in the brains from
mock-infected mice. Considered with the H&E data, our results show that the reversal
of hyperactivity seen in chronically infected mice treated with guanabenz is driven by
reduced neuroinﬂammation rather than parasite cyst burden. These ﬁndings imply that
some behavior changes induced by latent toxoplasmosis are more a consequence of
chronic neuroinﬂammation rather than a parasite-derived effector.
Guanabenz is detrimental to survival of chronically infected C57BL/6J mice. To
further examine the mechanism of guanabenz against Toxoplasma in vivo, we per-
formed a series of similar experiments in C57BL/6J mice to determine if the effects of
guanabenz were the same in an independent, nonisogenic mouse strain. Moreover,
C57BL/6J mice are commonly employed when investigating the immune response to
FIG 4 Guanabenz reduces inﬂammation in BALB/cJ mice in vitro and in vivo. (A to E) J774.1 cells were stimulated with LPS (10 ng/ml) in the presence or absence
of guanabenz (50 M) for 6 h. Levels of (A) IFN-, (B) TNF-, (C) IL-6, (D) IL-1 and (E) COX-2 mRNA were then measured by RT-qPCR. Values of infected cells
were normalized to untreated cells. Error bars indicate standard deviation of the mean (n 3); Student’s t test: *, P 0.05; ***, P 0.005; ****, P 0.0001. (F
and G) Representative images of H&E-stained brain sections from (F) mock-infected and (G) Toxoplasma-infected BALB/cJ mice treated with vehicle or GA as
indicated. Bar, 20 m. Yellow arrowheads highlight the perivascular cufﬁng associated with chronic Toxoplasma infection, which is not as pronounced in
GA-treated mice.
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FIG 5 Guanabenz reduces the number of CD45 cells in the brains of chronically infected BALB/cJ mice. (A) Brain tissue sections were stained with
anti-CD45 antibody (green). Hoechst stain was used to label nuclei (blue). Representative images for each group are shown. (B) Five random ﬁelds
(Continued on next page)
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Toxoplasma. C57BL/6J mice are highly susceptible to Toxoplasma infection, displaying
enhanced pathology and higher cyst burdens than more resilient strains like BALB/cJ
(25, 26).
Both male and female C57BL/6J mice were injected with a nonlethal dose of
Toxoplasma to establish chronic infection for 3 weeks (Fig. 6A). Mice were then ran-
domized into groups before being treated with either guanabenz or vehicle i.p. for
3 weeks. Unexpectedly, guanabenz caused nearly half of the chronically infected mice
to die within the ﬁrst 10 days of drug treatment (Fig. 6B). Mice that succumbed to the
guanabenz treatment developed classic symptoms of Toxoplasma encephalitis, includ-
ing lethargy, tremors, paralysis, and seizure. None of these mice showed signs of active
infection at the start of guanabenz treatment. These results suggest that the mice
experienced reactivation of encysted parasites rather than continuation of a severe
acute infection, but we cannot rule out the presence of lingering tachyzoites at the start
of drug treatment. The mice that survived the full drug treatment did not display any
symptoms of Toxoplasma encephalitis. Stratifying the groups by sex shows that the
FIG 5 Legend (Continued)
of view were selected under Hoechst staining for each mouse. Images were then randomized and prepared in a blind manner before the number
of CD45 cells was counted. Average number of CD45 cells per ﬁeld for each mouse was calculated and visualized. Error bars indicate standard
deviation of the mean. Bar, 50 m. Single replicate with one-way ANOVA, P 0.0001, followed by an unpaired, two-tailed Student t test: ns, P 0.5;
**, P 0.01; ***, P 0.001.
FIG 6 Effects of guanabenz on Toxoplasma cyst burden and behavior in C57BL/6 mice. (A) Male and female C57BL/6 mice were infected i.p. with
103 Pru tachyzoites. Following establishment of chronic infection at 21 days, groups were randomized to receive vehicle or guanabenz (GA
5 mg/kg/day i.p.). (B) Survival of mice in designated treatment groups. Single replicate with both sexes, log rank test, P 0.00232; ***, P 0.001.
(C) Brain cyst quantiﬁcation was performed in a blind manner on the vehicle- and GA-treated C57BL/6 mice. Error bars indicate standard deviation
of the mean. P values determined by Student’s t test: **, P 0.01; ***, P 0.001; ****, P 0.0001. (D) Following 3 weeks of treatment, locomotor
activity was recorded. Error bars indicate standard error of the mean. P values determined by Student’s t test: *, P 0.05; **, P 0.01.
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effects were equal in severity among both male and female C57BL/6J mice (see Fig. S1A
in the supplemental material).
Guanabenz increases cyst burden in C57BL/6J mice yet still reduces hyperac-
tivity and inﬂammation. In contrast to its effect in BALB/cJ mice, i.p. guanabenz led
to increased cyst burdens in the surviving C57BL/6J mice (Fig. 6C; Fig. S1B and C).
Despite the increase in brain cyst counts in the guanabenz-treated C57BL/6 mice,
the drug still reversed Toxoplasma-induced hyperactivity (Fig. 6D; Fig. S1D and E). The
experiment was repeated with the inclusion of mock-infected mice (Fig. 7A). The
decrease in hyperactivity was observed again in drug-treated chronically infected mice,
but there was no effect on activity level in the mock-infected mice receiving guanabenz
(Fig. 7B). These results match those observed with BALB/cJ mice.
Histological examination of the brains from infected C57BL/6J mice treated with
vehicle showed the overwhelming level of inﬂammation that is characteristic of latent
toxoplasmosis in this mouse strain (Fig. 8A). As previously reported (5), this inﬂamma-
tion does not localize to tissue cysts but remains concentrated around the vasculature
and diffuse throughout the cortex. When the brains were examined using IHC with
anti-CD45 antibody, the increased inﬂammation following Toxoplasma infection was
conﬁrmed (Fig. 8B). Quantiﬁcation of this inﬂammation shows a statistically lower
number of CD45 cells in the guanabenz-treated mice (Fig. 8C). These ﬁndings bolster
the idea that reversal of the hyperactive behavior depends more on controlling
neuroinﬂammation than cyst burden.
DISCUSSION
A key strategy that many parasites use to facilitate transmission involves behavioral
modiﬁcation of its host. Toxoplasma induces behavioral changes in chronically infected
mice and rats, which have been proposed to increase the odds that the rodent would
be captured and consumed by the deﬁnitive feline host of Toxoplasma. These behavior
changes include hyperactivity, cognitive impairment, and diminished fear of cat odors
(6, 8, 27). Several hypotheses that are not mutually exclusive have emerged to explain
how Toxoplasma may manipulate its host. Toxoplasma may cause structural damage to
the brain that affects neurobiological processes, but to date there is no consensus on
FIG 7 Guanabenz reverses Toxoplasma-induced hyperactivity, but not baseline activity, in C57BL/6J mice. (A) Female C57BL/6J mice were either mock infected
with PBS (Mock, white syringe) or infected with 103 Pru tachyzoites i.p. (Toxo, gray syringe) and allowed to progress to chronic infection for 21 days. Both groups
were then randomized into two treatment groups (vehicle or GA 5 mg/kg/day i.p.) and treated for 3 weeks. (B) Following 3 weeks of treatment, locomotor
activity was recorded. Single replicate, one-way ANOVA, P 0.0024, followed by an unpaired, two-tailed Student t test: *, P 0.05.
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FIG 8 Guanabenz reduces chronic inﬂammation in C57BL/6J mice with latent toxoplasmosis. (A) Representative H&E-stained images of mock-infected and
Toxoplasma-infected brains from vehicle control and GA-treated C57BL/6J mice. Staining patterns indicate a decrease in chronic inﬂammation and perivascular
cufﬁng (yellow arrowheads). There is also a lack of immune presence around tissue cysts (dashed yellow circle) in each group, which is typical of chronic
Toxoplasma infection. Bar, 20 m. (B) Representative brain tissue sections stained with anti-CD45 antibody (green) and Hoechst stain (blue) for designated
group. Bar, 50 m. (C) Five random ﬁelds of view were selected under Hoechst staining for each mouse. Images were then randomized and prepared in a blind
manner before the number of CD45 cells was counted. Average number of CD45 cells per ﬁeld for each mouse was calculated and visualized. Error bars
indicate standard error of the mean. Single replicate with one-way ANOVA, P 0.0001, followed by an unpaired, two-tailed Student t test: ns, P 0.5; *, P 0.05;
**, P 0.01; ***, P 0.001.
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the parasite’s distribution within the brain (5, 8, 28). Toxoplasma may release parasite
effector proteins that lead to altered levels of neurotransmitters or hormones in the
host, but attempts to restore neurotransmitter levels through pharmacological inter-
vention thus far have failed to reverse behavioral changes (11, 12). Finally, behavioral
changes could be an indirect consequence of the host immune response, such as
neuroinﬂammation (4, 29). The ﬁndings we present in this study lend support to this
third possibility.
We sought to determine if behavioral changes correlate with brain cyst burden by
taking advantage of guanabenz, an FDA-approved drug for hypertension that was
recently shown to also have activity against apicomplexan parasites (19, 20). After
trying several doses and various routes of administration, and checking for different
responses between sexes, we optimized conditions that reproducibly lower brain cyst
burden by 70 to 80% in BALB/cJ mice (Fig. 1). The establishment of this mouse model
for brain cyst reduction should prove invaluable in the future study of questions
designed to interrogate effects of latent toxoplasmosis on behavior. For this study, we
chose to examine hyperactivity, as it was the most consistent and reproducible
behavioral change observed in our hands. We also attempted to examine anxiety,
working memory, and odor aversion, but these behavioral assays produced inconsis-
tent results between experiments.
Three-week treatment of chronically infected BALB/cJ mice with guanabenz consis-
tently reversed Toxoplasma-induced hyperactivity, leading us to believe that cyst
burden correlated with this change in behavior (Fig. 2). However, the rescue from
hyperactivity was also seen when guanabenz was administered through oral routes
that had no impact on brain cyst counts (Fig. 3). The difference between oral and i.p.
administration is likely due to slower absorption through the gut and the effects of
ﬁrst-pass metabolism. Consistent with this idea, there was a delay in the hypotensive
effects caused by GA in the mice that were given drug by gavage. Mice given i.p. GA
showed signs of hypotension (such as staggering gait) within minutes of injection, but
mice given GA by gavage did not display hypotensive side effects until 30 min later.
Importantly, treatment of chronically infected C57BL/6 mice did not lower cyst counts
and yet still reduced parasite-induced hyperactivity (Fig. 6 and 7). Taken together, these
results suggest that the number of brain cysts is not associated with this change in
behavior.
We then addressed an alternative possibility: the behavioral changes induced by
latent toxoplasmosis could arise from chronic neuroinﬂammation. Indeed, guanabenz
has previously been shown to have anti-inﬂammatory properties and is currently in
clinical trials for multiple sclerosis (22–24). To test this idea, we examined brain tissue
harvested from guanabenz-treated or vehicle-treated mice that were harboring latent
toxoplasmosis. In addition to H&E staining, we used anti-CD45 staining to quantify the
degree of immune presence in the brain (Fig. 4 and 5). Consistent with other reports (5,
11), the latently infected brains in our study continued to show inﬂammation despite
the absence of acute toxoplasmosis symptoms. Guanabenz reduced neuroinﬂamma-
tion in mice suffering from chronic infection and was the common feature observed in
any mouse that exhibited a reversal of hyperactivity to baseline levels. Our data show
that the restoration of Toxoplasma-induced hyperactivity correlates with reduced neu-
roinﬂammation rather than brain cyst burden. Dissecting the nature of this chronic
inﬂammatory response should reveal better insights into the mechanisms underlying
the behavioral changes observed during latent toxoplasmosis.
Neuroinﬂammation has been repeatedly suggested as a major player in global CNS
dysfunction. The brain is considered an immune-privileged site with its own resident
macrophage (microglia) to maintain homeostasis. Elevated levels of inﬂammation have
been associated with behavioral changes in rodent models and have been linked with
some of the neurological diseases with which Toxoplasma correlates most strongly in
humans, such as schizophrenia (30). Schizophrenic patients given antipsychotics with
anti-Toxoplasma activity show a decrease in symptoms along with a decrease in
inﬂammatory markers (31). Additionally, other pathogens, including herpes simplex
Reversing Behavior Changes in Toxoplasma-Infected Mice ®
March/April 2019 Volume 10 Issue 2 e00381-19 mbio.asm.org 11
virus, have been proposed to be a factor in the development of neuropathological
diseases, in particular Alzheimer’s disease (32).
Our ﬁndings bolster the idea that neuroinﬂammatory mechanisms driven by Toxo-
plasma infection inﬂuence host CNS function. It has been proposed that extensive
cytokine secretion and NF-B activation induced by the parasite mediate neurobehav-
ioral effects (33). An analysis of synaptosomal protein composition found that
inﬂammation-related responses are upregulated during chronic toxoplasmosis in mice
(4). In addition, multiple transcriptomic analyses show immune-speciﬁc transcripts to
be among the most highly upregulated in chronic infection (5, 34, 35). Immune
inﬁltration was also found to persist for weeks in mice that overcame infection with an
attenuated strain of Toxoplasma that formed no detectable cysts in vivo (14).
The fact that we observed vastly different effects of guanabenz on two different
strains of mice highlights that in vivo studies of Toxoplasma should be performed in
multiple (nonisogenic) strains of mice before ﬁrm conclusions can be drawn. BALB/cJ
and C57BL/6J exhibit important differences in their immune response to Toxoplasma
infection, and the use of guanabenz may be helpful in future studies designed to
further interrogate the molecular differences between these strains of mice in response
to infection. C57BL/6J mice show greatly enhanced pathology due to differences
mapped to the major histocompatibility complex (MHC) class II haplotype, which is
found on antigen-presenting cells (25). When C57BL/6J mice were treated with gua-
nabenz, almost half of the drug-treated group died after displaying signs of acute
toxoplasmosis that could have arisen from reactivation of tissue cysts or lingering
tachyzoites that may have been present during administration of guanabenz. We
suspect that the anti-inﬂammatory effects, especially the guanabenz-mediated reduc-
tion in IFN- known to be critical in controlling pathogenesis (Fig. 4), are reducing the
ability of the more susceptible host to control reactivated parasites. It is also important
to emphasize that guanabenz activity differed when administered orally instead of
intraperitoneally. It is likely that the slower absorption through the gut during intra-
gastric dosing, along with ﬁrst-pass metabolism effects, prevented brain cysts from
being signiﬁcantly affected.
Despite longer treatment times, guanabenz was unable to lower cyst burden further
or eliminate cysts altogether. Curiously, similar results were seen with endochin-like
quinolones, which inhibit the parasite cytochrome bc1 complex (36), and an inhibitor of
Toxoplasma gondii calcium-dependent protein kinase 1 referred to as compound 32
(37). It is unclear why, in all cases, brain cyst counts could not be lowered beyond
80%. Future studies that monitor where these intractable populations hide in the
brain may shed light on this conundrum. We did not measure tachyzoite levels in the
brain, which could also have given rise to the residual tissue cysts. Cyst eradication is
a vital area for continued study and has important clinical ramiﬁcations. Not only do
cysts give rise to chronic infection in humans and life-threatening reactivation of acute
infection in immunocompromised patients, but they have also been linked to neuro-
psychiatric disorders such as schizophrenia, intermittent explosive disorder, and suicide
(10, 29). Aside from cyst reduction, our studies also suggest that certain neuropsychi-
atric disorders, if linked to latent toxoplasmosis, might be controlled through anti-
inﬂammatory therapies.
MATERIALS AND METHODS
Parasite strains and culture. Toxoplasma gondii parasites (type II Prugniaud [Pru] strain) were
collected as tissue cysts from chronically infected BALB/c mice and used to infect human foreskin
ﬁbroblasts (HFF). The infected cultures were maintained in Dulbecco’s medium supplemented with 1%
heat-inactivated fetal bovine serum (FBS) in a humidiﬁed incubator at 37°C with 5% CO2. To ensure their
developmental capacity, tachyzoites were maintained in culture no more than 15 passages. Parasites
were tested for mycoplasma using PCR as previously described prior to use in mice (38).
Mouse strains and infection. The mice used in this study were housed in American Association for
Accreditation of Laboratory Animal Care (AAALAC)-approved facilities at either the Indiana University
School of Medicine Laboratory Animal Research Center (LARC) or the IUPUI Science Animal Research
Center (SARC). The Institutional Animal Care and Use Committee (IACUC) at Indiana University School of
Medicine approved the use of all animals and procedures (IACUC protocol numbers 10852 and 11376).
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BALB/cJ mice were purchased from the Jackson Laboratory (Bar Harbor, ME) at 5 weeks of age. The
mice were allowed to acclimate for 1 week before being intraperitoneally infected with 104 Pru
tachyzoites suspended in 100 l of autoclaved, ﬁlter-sterilized PBS. C57BL/J6 mice, also purchased from
the Jackson Laboratory at 5 weeks of age, were infected with 103 Pru tachyzoites after acclimation. Mice
were routinely observed multiple times a day throughout the course of acute infection. Mock-infected
animals were handled in an identical manner and injected with the same volume of sterile PBS. After
21 days postinfection, mice were randomized into treatment groups. Blood samples were extracted by
cardiac puncture to conﬁrm parasite infection by serological analysis using a dot blot containing parasite
lysate.
Drug administration. All drug treatments in this study were administered after mice had progressed
to the chronic stage of infection (21 days postinfection), at which point they were no longer symptomatic
and had started to regain weight. Guanabenz was delivered i.p. at 5 mg/kg/day at the same time every
day for 3 to 6 weeks depending on the experiment. For oral gavage, the dosage was increased to
10 mg/kg/day but administered at the same time as in the i.p. group. For the medicated feed group, fresh
feed was made every other day and old feed was removed when fresh feed was added. To minimize the
inﬂuence of feed buried in the cage bedding on fresh feed consumption, the cages for this group were
changed every 4 days. Feed (5 g/mouse/day) was weighed out, placed in a metal bowl, combined with
5.5 ml water per g of feed, and allowed to absorb for 15 min. Separate bowls were used for the vehicle
group and drug treatment group. The calculated dose of guanabenz for 10 mg/kg/day/mouse was
suspended in 10 ml of corn oil (or 10 ml of corn oil alone for the vehicle control) and added to the wet
feed before being mixed with a potato masher and placed in a plastic weigh boat. The weigh boat was
placed on the ﬂoor of the cage where the mice could easily reach it.
Locomotor activity. Twenty to 24 h after the last drug treatment, mice were moved to the testing
room and allowed to acclimate for 30 min. Prior to performing the locomotive assay, mice were
evaluated by an individual blind to the study groups, and any mouse that exhibited signs of illness or
a symptom that would limit movement (such as limb paralysis) was noted and removed from the
mobility analysis. In total, two vehicle-treated mice and two guanabenz-treated mice were excluded from
the experiment shown in Fig. 7. Individual mice were then placed in a VersaMax locomotor activity
testing chamber (AccuScan Instruments), and locomotion was recorded for 30 min. The activity chamber
measured 40 by 40 cm and was housed within a sound-attenuating chamber with a house light and fan
for ventilation. The chamber was equipped with photocell beams located 2 cm above the Plexiglas ﬂoor
to record locomotor activity. Mice were returned to their home cage after the 30-min test session.
Brain cyst burden and histological analysis. Brains were extracted and cut in half; the left
hemisphere was processed for cyst quantiﬁcation, and the right hemisphere was ﬁxed in 10% neutral
buffered formalin (NBF) for histology. Cyst burden was quantiﬁed as previously described (20). Brieﬂy, the
dissected tissue was homogenized in 650 l of sterile PBS using a mortar and pestle. A 250-l aliquot of
homogenate was ﬁxed using 3% methanol-free formaldehyde for 20 min. The homogenate was blocked
using 3% bovine serum albumin (BSA) in 0.2% Triton X-100 before staining with 1:250 rhodamine-
conjugated Dolichos biﬂorus lectin (Vector Laboratories) to visualize the cyst wall. Five-microliter aliquots
of stained homogenate were placed on a coverslip and sealed before imaging. Stained samples were
prepared in a blind manner before cysts were counted under 20 magniﬁcation.
Following a week in 10% NBF, the ﬁxed tissue was processed using dehydration through graded
ethanol and xylene before being embedded into parafﬁn blocks. Blocks were cut into 5-m sections
using a microtome and then heat ﬁxed to glass slides. Slides were stained with hematoxylin and eosin
and then viewed on a Leica DM 2500 microscope. Representative images were taken from each
treatment and infection status group, with particular focus given to the perivascular regions.
For IHC, slides were rehydrated through graded xylene and methanol before antigen retrieval using
citric buffer. Sections were then blocked using 10% normal goat serum, 1% bovine serum albumin in
PBS-T for 2 h at room temperature. Rat anti-mouse CD45 antibody (Stem Cell Technologies; lot no.
BX30892) diluted 1:400 in blocking buffer was added for 1 h before repeat washes in PBS-T. Goat anti-rat
secondary antibody (Invitrogen; Alexa Fluor 488 lot no. 1928689) diluted 1:200 in blocking buffer was
added for 1 h in the dark. After serial washes with PBST, sections were incubated with 20 g/ml Hoechst
33342 in PBST for 10 min to visualize nuclei. Coverslips were mounted using PermaFluor mountant
medium (no. TA030FM; Thermo). Slides were viewed using a Nikon Eclipse E100080i microscope, and
digital images were captured with a Hamamatsu C474295 charge-coupled device camera using NIS
elements software. Five random ﬁelds of view were selected and captured while viewing nuclei. Images
were prepared in a blind manner and randomized before CD45 cells were counted in each image. The
average number of CD45 cells was calculated for each mouse.
Measurement of mRNA levels. J774.1 cells at 1 105 were seeded into 6-well plates and allowed
to adhere overnight. Cells were stimulated with lipopolysaccharide (10 ng/ml) for 6 h in the presences or
absence of guanabenz (50 M) as previously reported (23). Total RNA was isolated from the cells using
TRIzol LS (Invitrogen), and cDNA was generated using Omniscript (Qiagen). RT-qPCR was carried out
using SYBR Green real-time PCR master mixes (Invitrogen) and the StepOnePlus Real system (Applied
Biosystems). Relative levels of transcripts were calculated with the ΔΔCT method using GAPDH as the
internal control. The relative levels of the target mRNAs from the untreated cells were adjusted to 1 and
served as the basal control value. Each experiment was performed three times, each with three technical
replicates. The primers used are listed in Table S1 in the supplemental material.
Statistics. Statistical analysis was performed using GraphPad Prism v7.03. For data sets comparing
two groups, statistical signiﬁcance was determined using Student’s t test. If more than two groups were
compared, the data sets were analyzed using one-way ANOVA to determine statistical signiﬁcance before
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secondary analysis with Student’s t test. Survival data were analyzed using a log rank test. P values of
0.05 were considered statistically signiﬁcant.
SUPPLEMENTAL MATERIAL
Supplemental material for this article may be found at https://doi.org/10.1128/mBio
.00381-19.
FIG S1, EPS ﬁle, 2.1 MB.
TABLE S1, DOCX ﬁle, 0.01 MB.
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